Aranda Richard, Chief Medical Officer, has engaged in a series of transactions involving shares of Gossamer Bio, Inc. (GOSS) as disclosed in SEC Form 4 filings. Over the course of 25 trades, Richard’s activity has been exclusively tied to GOSS, with no transactions reported for other companies. Notably, all transactions have been classified as either acquisitions (code "A") or dispositions (code "D"), with no monetary value assigned to any of these trades. This suggests the transactions may involve non-monetary transfers, such as the exercise of stock options or the receipt of equity awards, rather than open market purchases or sales.
Richard’s recent activity has been concentrated around specific dates, particularly March 19, 2026, when 22 transactions were executed. Of these, 11 were acquisitions and 11 were dispositions, indicating a balanced approach to managing equity holdings during this period. Earlier transactions occurred on January 2, 2026, and October 1, 2025, both involving acquisitions. The absence of any reported buy or sell values across all trades underscores the non-monetary nature of these activities. This pattern reflects a focus on equity management within a single company, GOSS, without a discernible bias toward accumulating or reducing shares.
AI-assisted summary